213 results about "Ischaemia reperfusion" patented technology

Ischemia-reperfusion injury commonly results from any surgical procedure requiring stopping of blood supply to an organ followed by reperfusion such as in heart bypass, angioplasty or organ transplant. The invention discloses a method to harness the innate power of repetitive transient ischemia in protecting organs against imminent ischemia-reperfusion, or any patho-physiological insults. This method of optimal remote ischemic preconditioning (ORIP) comprises of utilizing a pair of programmable pneumatic cuffs that inflate/deflate alternately occluding blood circulation to each of the limbs for pre-defined time intervals. The apparatus delivers maximal ORIP dose in shortest possible time either as an EMS procedure during patient transportation to hospital, as elective pre-surgery treatment, or in critical care for preventing multiple-organ-dysfunction-syndrome. ORIP can be self-administered and remotely monitored by clinician especially in chronic patients for homeostasis of malfunctioning target organs. ORIP may also be deployed as adjunct in angioplasty, gene/stem cell heart repair therapies.

The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

Methods and compositions including combined use of a serine protease inhibitor and adenosine when administered as a single pharmaceutical composition, concomitantly or sequentially in any order to a living subject for preventing organ ischemia or reperfusion injury. The methods and compositions disclosed herein can be used in such procedures as cardiac surgery, non-surgical cardiac revascularization, organ transplantation, perfusion, ischemia, reperfusion, ischemia-reperfusion injury, oxidant injury, cytokine induced injury, shock induced injury, resuscitations injury or apoptosis.

Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

The invention discloses an application of 5,7-dihydroxy-4'-methoxy flavone preparation extracted from snow lotus in preparation of a medicament for treating ischemic stroke. By effectively extracting the 5,7-dihydroxy-4'-methoxy flavone preparation from the snow lotus and establishing an ischemia reperfusion model of a mouse, the influence of acacetin on the infarct volume and the neurologic impairment caused by ischemia reperfusion injury of the mouse is observed. The study carried out by establishing an SH-SY5Y cell OGD model, testing the cell viability and the cell apoptosis, and demonstrating the integral level of the acacetin shows that the acacetin has the effect of significantly reducing the infarct volume, improving the neurologic function score, promoting the cell survival and reducing the cell apoptosis, clarifies that the acacetin has a neurologic protection effect on the cerebral ischemia reperfusion injury and proves that the 5,7-dihydroxy-4'-methoxy flavone preparation can be well applied to preparing the medicament for treating ischemic stroke and has wide application value.

The invention relates the use of codonopsis pilosula and astragalus root composition in treating ischemic heart diseases, wherein the composition has functions for treating myocardial ischemia, myocardiac infarction, myocardiopathy, and for treating thrombogenesis, lowering blood viscosity, and reducing platelet aggregation.

The invention relates to the field of medicines and discloses a pharmaceutical composition for treating cardiovascular diseases. The composition comprises piceatannol 3'-O-glucoside, polydatin and a piceatannol 3'-O-glucoside derivative. Research found that the composition significantly improves the area of cerebral infarction and the area of myocardial ischemia after ischemia-reperfusion, fundamentally improves various damages caused by ischemia for patients with ischemic cardiovascular diseases, and has a good clinical application prospect.

Preparation and detection methods of an animal heart single-cell suspension are disclosed. The preparation method includes 1) preparing an animal heart ischemia reperfusion model; 2) preparing an animal isolated hear tissue, flushing the tissue to remove blood, adding heart digestive juice, cutting the tissue into pieces, fully mixing the tissue pieces with the digestive juice and performing digestion; and 3) filtering a mixture solution obtained in the step 2), performing centrifugation, removing a supernatant liquid, terminating digestion, adding a phosphate buffer liquid for suspension, adding an erythrocyte lysis solution, performing centrifugation, removing a supernatant liquid, and adding a phosphate buffer liquid for suspension to obtain the animal heart single-cell suspension. Thepreparation method can reduce destroy to cells, and the single-cell suspension preparation method which is reliable and stable is provided. The number of cells in the prepared suspension is high. Thedetection method is simple to operate and comprehensive in data.

This invention is related to new nitrogenated trans-stilbene analog compounds, more specifically, imine, pyrrol and Indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

The present invention relates to a new use of 20(S)-protopanoxadiol, and in particular, to an application of 20(S)-protopanoxadiol in preparing the medicines for preventing and treating ischemic heart diseases. Pharmacodynamics studies have found that 20(S)-protopanoxadiol can reduce myocardial histological damages caused by ischemia and ischemia reperfusion, reduce enzyme indicators related to infarct size and myocardial necrosis, and reduce the drift of J-spot on an electrocardiogram.

The invention relates to stephanine and its pharmaceutically acceptable salt and an application of a solvate for preparing an antiarrhythmic medicine, which belongs to the technical field of medicine. A structural formula of stephanine is shown as a formula (I); the researches on chloroform-induced mice arrhythmia show that stephanine can resist chloroform-induced ventricular fibrillation, preliminary determination is confirmed that the stephanine has antiarrhythmic effect; then barium chloride-induced rat ventricular rhythm test, aconitine intravenous injection-induced rat cardiac rhythm test and rat myocardial ischemia and ischemia reperfusion arrhythmia test are carried out, so that stephanine has good antiarrhythmic effect, and provides a good base for preparing various antiarrhythmic medicines next time.

The invention relates to an application of natural compound epicatechin gallate obtained from tea and derivatives thereof for treating or preventing myocardial infarction and other ischemic heart diseases. The compound is used for preventing the myocardial injury of the heart caused by ischemia-reperfusion, and is a medicament for potentially treating or preventing the heart ischemia/reperfusion injury. Particularly, the compound has a novel effect on protecting the heart and has a function that the enhancement of the myocardial contractility does not depend on the increase of the concentration of calcium ions in myocardial cells. In the invention, it is discovered that the epicatechin gallate (ECG) and the derivatives thereof have pharmacological pre-adaptation functions and have pharmacological post-adaptation functions for the first time, thus the ECG and the derivatives thereof are possibly novel medicaments for treating or preventing myocardial infarction and other ischemic heart diseases. The ECG and the derivatives thereof not only can be used for clinically treating congestive heart diseases through pharmacological post-adaptation but also can be used for medically preventing the patient who suffers from myocardial infarction and then is cured from being subjected to myocardial infarction again through pharmacological pre-adaptation.

The invention relates to a high-purity polyphyllin VI preparation method and an application, and belongs to the field of Chinese herbal medicine extraction and separation. The method includes the specific steps: roughly crushing Chinese paris rhizome or wake robin medicinal materials, performing ethanol extraction; sequentially performing macroporous adsorption resin, silica gel and reverse-phase material column chromatography on extracting solution; taking ethyl acetate, ethanol and water as eluting agents and filtering, washing and drying sedimentation portions after recovering solvents by eluent to obtain high-purity polyphyllin VI. The method has the advantages that the operation steps are easily repeated, conditions are easily controlled and amplified, the solvents are low in toxicity and easy to recover, and the like. The obtained polyphyllin VI is basically free from organic solvent residues, and the purity of the polyphyllin VI reaches 98% or more. After pharmacodynamical research of the influence of mouse normal pressure hypoxia tolerance, mouse brain ischemia caused by common carotid artery ligation, rat myocardium injury caused by ischemia reperfusion, myocardial infarction caused by rat isolated heart myocardial ischemia and the like, the polyphyllin VI serving as a final product is good in effect and can be used for developing products for treating cardiovascular and cerebrovascular diseases.

The invention discloses an application of polysaccharides of taxus mairei in the preparation of drugs for preventing and controlling the myocardial ischemia reperfusion injury. The drugs can be any pharmaceutically acceptable preparation, and the content of the polysaccharides of taxus mairei in the preparation by weight percent is not less than 60 percent; the polysaccharides of taxus mairei can improve the LV-dp/dXmaX and SOD ability after the myocardial ischemia reperfusion, improve the myocardial compliance, significantly reduce the serum LDH, the serum cTnT and the MDA level after the myocardial ischemia reperfusion and reduce the myocardial injury; the polysaccharides of taxus mairei can significantly inhibit and lower the FaS mRNA and the protein expression thereof, the MCP-1 mRNA and the protein expression thereof and the NCF-47K mRNA and the protein expression thereof after the myocardial ischemia reperfusion, thereby further inhibiting the myocardial cell apoptosis after the myocardial ischemia reperfusion. Therefore, the polysaccharides of taxus mairei have the effects of preventing and controlling the myocardial ischemia reperfusion injury and developing a new clinical application field of the polysaccharides of taxus mairei.

The invention relates to the field of medicines and discloses a pharmaceutical composition and uses thereof. The composition comprises piceatannol 3'-O-glucoside, polydatin and a piceatannol 3'-O-glucoside derivative. Research found that the composition significantly improves the area of cerebral infarction and neurological functions after ischemia-reperfusion, fundamentally improves various damages caused by ischemia for patients with cerebrovascular diseases, has excellent treating functions for cerebrovascular diseases, and has a good clinical application prospect.